GIMOTI Patent Extension Secures Market Exclusivity Through 2036 for Gastroparesis Treatment
Evoke Pharma (NASDAQ: EVOK) has received a Notice of Allowance from the USPTO for a patent application covering GIMOTI® (metoclopramide nasal spray) use in moderate to severe gastroparesis patients. The new patent, upon issuance, will extend market exclusivity until December 2036 and will be listed in the FDA’s Orange Book. … Read more